Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the safety of AdGVPEDF.11D when given to
patients with "wet" age-related macular degeneration (AMD). AdGVPEDF.11D is a replication
deficient (E1, E3 and E4 deleted) adenovirus vector containing the gene for the PEDF (pigment
epithelium-derived factor) protein. PEDF is a protein that naturally exists in the human eye,
but whose levels are altered in diseases characterized by ocular neovascularization like AMD.
The PEDF protein is known to have anti-angiogenic effects or, in other words, it has the
ability to inhibit growth of new blood vessels.
AdGVPEDF.11D will be delivered once via intravitreal injection into one eye. The injected eye
will be the eye with the worst visual acuity.